GrayBug is a biopharmaceutical company focused on developing sustained-release drug delivery systems for ocular diseases, utilizing proprietary polymer-based formulations. Their technology addresses the challenge of frequent intravitreal injections, improving patient compliance and treatment outcomes for conditions like age-related macular degeneration.
Funding
Funding not disclosed
Founders
Product
Problem
Frequent intravitreal injections are the standard treatment for many retinal diseases, but they pose a significant burden on patients, leading to poor compliance and suboptimal treatment outcomes. The need for repeated clinic visits and injections increases the risk of complications and reduces patients' quality of life.
Solution
GrayBug Vision is developing sustained-release drug delivery systems for ocular diseases, aiming to reduce the frequency of intravitreal injections. Their proprietary polymer-based formulations are designed to release therapeutic agents over extended periods, potentially improving patient compliance and treatment outcomes. By minimizing the need for frequent injections, GrayBug Vision seeks to provide a more convenient and effective treatment option for patients with retinal diseases. This approach aims to address the limitations of current therapies and improve the overall management of conditions such as age-related macular degeneration and diabetic macular edema.
Target Audience
The primary target audience includes patients with retinal diseases such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, as well as ophthalmologists and retina specialists seeking improved drug delivery options.
Features
- Proprietary polymer-based formulations for sustained drug release in the eye
- Injectable microparticle suspensions designed for depot formation in the vitreous
- Controlled drug release kinetics to maintain therapeutic drug levels over months
- Biodegradable polymers that eliminate the need for surgical removal
- Potential for reduced injection frequency compared to standard intravitreal injections